Toxicology of autoimmune diseases

Chemical Research in Toxicology

Volumn 23, Issue 3, 2010, Pages 455-466

  Pollard, K Michael ^a   Hultman, Per ^a   Kono, Dwight H ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; DNA; SILICON DIOXIDE; TOXIC SUBSTANCE;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE PREDISPOSITION; DNA METHYLATION; GENE DELETION; HUMAN; IMMUNE RESPONSE; LIVER DISEASE; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; TOXICOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 77949418686     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx9003787     Document Type: Review

References (168)

1. Tan, E. M., Chan, E. K., Sullivan, K. F., and Rubin, R. L. (1988) Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin. Immunol. Immunopathol. 47, 121-141.
2. Tan, E. M. (1989) Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology. AdV. Immunol. 44, 93-151.
3. Lam-Tse, W. K., Lernmark, A., and Drexhage, H. A. (2002) Animal models of endocrine/organ-specific autoimmune diseases: Do they really help us to understand human autoimmunity? Springer Semin. Immunopathol. 24, 297-321.
4. Badenhoop, K., and Boehm, B. O. (2004) Genetic susceptibility and immunological synapse in type 1 diabetes and thyroid autoimmune disease. Exp. Clin. Endocrinol. Diabetes 112, 407-415.
5. Dedeoglu, F. (2009) Drug-induced autoimmunity. Curr. Opin. Rheumatol. 21, 547-551.
6. Vedove, C. D., Del Giglio, M., Schena, D., and Girolomoni, G. (2009) Drug-induced lupus erythematosus. Arch. Dermatol. Res. 301, 99-105.
7. Rubin, R. L. (2005) Drug-induced lupus. Toxicology 209, 135-147.
8. Totoritis, M. C., and Rubin, R. L. (1985) Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad. Med. 78, 149-152, 155-161.
9. Rubin, R. L., Teodorescu, M., Beutner, E. H., and Plunkett, R. W. (2004) Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus. Lupus 13, 249-256.
10. Cornacchia, E., Golbus, J., Maybaum, J., Strahler, J., Hanash, S., and Richardson, B. (1988) Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140, 2197-2200.
11. Yung, R. L., Quddus, J., Chrisp, C. E., Johnson, K. J., and Richardson, B. C. (1995) Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J. Immunol. 154, 3025-3035.
12. Richardson, B. C. (2008) Epigenetics and autoimmunity. Overview. Autoimmunity 41, 243-244.
13. Lu, Q., Wu, A., and Richardson, B. C. (2005) Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J. Immunol. 174, 6212-6219.
14. Ballestar, E., Esteller, M., and Richardson, B. C. (2006) The epigenetic face of systemic lupus erythematosus. J. Immunol. 176, 7143-7147.
15. Rubin, R. L., Bell, S. A., and Burlingame, R. W. (1992) Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J. Clin. InVest. 90, 165-173.
16. Rubin, R. L., and Kretz-Rommel, A. (1999) Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus. EnViron. Health Perspect. 107 (Suppl. 5), 803-806.
17. Kretz-Rommel, A., and Rubin, R. L. (1999) Persistence of autoreactive T cell drive is required to elicit anti-chromatin antibodies in a murine model of drug-induced lupus. J. Immunol. 162, 813-820.
18. Kretz-Rommel, A., and Rubin, R. L. (2000) Disruption of positive selection of thymocytes causes autoimmunity. Nat. Med. 6, 298-305.
19. Rubin, R. L., and Kretz-Rommel, A. (2001) A nondeletional mechanism for central T-cell tolerance. Crit. ReV. Immunol. 21, 29-40.
20. Parks, C. G., Conrad, K., and Cooper, G. S. (1999) Occupational exposure to crystalline silica and autoimmune disease. EnViron. Health Perspect. 107 (Suppl. 5), 793-802.
21. Otsuki, T., Maeda, M., Murakami, S., Hayashi, H., Miura, Y., Kusaka, M., Nakano, T., Fukuoka, K., Kishimoto, T., Hyodoh, F., Ueki, A., and Nishimura, Y. (2007) Immunological effects of silica and asbestos. Cell. Mol. Immunol. 4, 261-268.
22. Hamilton, J. A. (2003) Nondisposable materials, chronic inflammation, and adjuvant action. J. Leukocyte Biol. 73, 702-712.
23. Hamilton, R. F., Jr., Thakur, S. A., and Holian, A. (2008) Silica binding and toxicity in alveolar macrophages. Free Radical Biol. Med. 44, 1246-1258.
24. Thakur, S. A., Beamer, C. A., Migliaccio, C. T., and Holian, A. (2009) Critical role of MARCO in crystalline silica-induced pulmonary inflammation. Toxicol. Sci. 108, 462-471.
25. Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., and Latz, E. (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856.
26. Ting, J. P., Willingham, S. B., and Bergstralh, D. T. (2008) NLRs at the intersection of cell death and immunity. Nat. ReV. Immunol. 8, 372-379.
27. Willingham, S. B., and Ting, J. P. (2008) NLRs and the dangers of pollution and aging. Nat. Immunol. 9, 831-833.
28. Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., and Tschopp, J. (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677.
29. Rimal, B., Greenberg, A. K., and Rom, W. N. (2005) Basic pathogenetic mechanisms in silicosis: Current understanding. Curr. Opin. Pulm. Med. 11, 169-173.
30. Davis, G. S., Leslie, K. O., and Hemenway, D. R. (1998) Silicosis in mice: Effects of dose, time, and genetic strain. J. EnViron. Pathol., Toxicol. Oncol. 17, 81-97.
31. Granum, B., Gaarder, P. I., Groeng, E., Leikvold, R., Namork, E., and Lovik, M. (2001) Fine particles of widely different composition have an adjuvant effect on the production of allergen-specific antibodies. Toxicol. Lett. 118, 171-181.
32. Brown, J. M., Archer, A. J., Pfau, J. C., and Holian, A. (2003) Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice. Clin. Exp. Immunol. 131, 415-421.
33. Brown, J. M., Pfau, J. C., and Holian, A. (2004) Immunoglobulin and lymphocyte responses following silica exposure in New Zealand mixed mice. Inhalation Toxicol. 16, 133-139.
34. Pfau, J. C., Brown, J. M., and Holian, A. (2004) Silica-exposed mice generate autoantibodies to apoptotic cells. Toxicology 195, 167-176.
35. Rogers, N. J., Lees, M. J., Gabriel, L., Maniati, E., Rose, S. J., Potter, P. K., and Morley, B. J. (2009) A defect in Marco expression contributes to systemic lupus erythematosus development via failure to clear apoptotic cells. J. Immunol. 182, 1982-1990.
36. Pfau, J. C., Sentissi, J. J., Weller, G., and Putnam, E. A. (2005) Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA. EnViron. Health Perspect. 113, 25-30.
37. Noonan, C. W., Pfau, J. C., Larson, T. C., and Spence, M. R. (2006) Nested case-control study of autoimmune disease in an asbestosexposed population. EnViron. Health Perspect. 114, 1243-1247.
38. Pfau, J. C., Sentissi, J. J., Li, S., Calderon-Garciduenas, L., Brown, J. M., and Blake, D. J. (2008) Asbestos-induced autoimmunity in C57BL/6 mice. J. Immunotoxicol. 5, 129-137.
39. Kettaneh, A., Al Moufti, O., Tiev, K. P., Chayet, C., Toledano, C., Fabre, B., Fardet, L., and Cabane, J. (2007) Occupational exposure to solvents and gender-related risk of systemic sclerosis: a metaanalysis of case-control studies. J. Rheumatol. 34, 97-103.
40. Posada de la Paz, M., Philen, R. M., and Borda, A. I. (2001) Toxic oil syndrome: The perspective after 20 years. Epidemiol. ReV. 23, 231-247.
41. Patterson, R., and Germolec, D. (2005) Review article toxic oil syndrome: Review of immune aspects of the disease. J. Immunotoxicol. 2, 51-58.
42. Bell, S. A., Hobbs, M. V., and Rubin, R. L. (1992) Isotype-restricted hyperimmunity in a murine model of the toxic oil syndrome. J. Immunol. 148, 3369-3376.
43. Berking, C., Hobbs, M. V., Chatelain, R., Meurer, M., and Bell, S. A. (1998) Strain-dependent cytokine profile and susceptibility to oleic acid anilide in a murine model of the toxic oil syndrome. Toxicol. Appl. Pharmacol. 148, 222-228.
44. Cai, P., Khan, M. F., Kaphalia, B. S., and Ansari, G. A. (2005) Immunotoxic response of oleic acid anilide and its hydrolysis products in female MRL (+/+) mice. J. Immunotoxicol. 2, 231-236.
45. Hard, G. C. (2002) A search for an animal model of the Spanish toxic oil syndrome. Food Chem. Toxicol. 40, 1551-1567.
46. Hultman, P., Bell, L. J., Enestrom, S., and Pollard, K. M. (1992) Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in inbred, congenic, and intra-H-2 recombinant strains. Clin. Immunol. Immunopathol. 65, 98-109.
47. Hultman, P., Johansson, U., Turley, S. J., Lindh, U., Enestrom, S., and Pollard, K. M. (1994) Adverse immunological effects and autoimmunity induced by dental amalgam and alloy in mice. FASEB J. 8, 1183-1190.
48. Havarinasab, S., Johansson, U., Pollard, K. M., and Hultman, P. (2007) Gold causes genetically determined autoimmune and immunostimulatory responses in mice. Clin. Exp. Immunol. 150, 179-188.
49. Johansson, U., Hansson-Georgiadis, H., and Hultman, P. (1997) Murine silver-induced autoimmunity: Silver shares induction of antinucleolar antibodies with mercury, but causes less activation of the immune system. Int. Arch. Allergy Immunol. 113, 432-443.
50. Baserga, S. J., Yang, X. D., and Steitz, J. A. (1991) An intact Box C sequence in the U3 snRNA is required for binding of fibrillarin, the protein common to the major family of nucleolar snRNPs. EMBO J. 10, 2645-2651.
51. Yang, J. M., Hildebrandt, B., Luderschmidt, C., and Pollard, K. M. (2003) Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex. Arthritis Rheum. 48, 210-217.
52. Van Eenennaam, H., Vogelzangs, J. H., Bisschops, L., Te Boome, L. C., Seelig, H. P., Renz, M., De Rooij, D. J., Brouwer, R., Pluk, H., Pruijn, G. J., Van Venrooij, W. J., and Van Den Hoogen, F. H. (2002) Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin. Exp. Immunol. 130, 532-540.
53. Lynes, M. A., Fontenot, A. P., Lawrence, D. A., Rosenspire, A. J., and Pollard, K. M. (2006) Gene expression influences on metal immunomodulation. Toxicol. Appl. Pharmacol. 210, 9-16.
54. Silva, I. A., Nyland, J. F., Gorman, A., Perisse, A., Ventura, A. M., Santos, E. C., Souza, J. M., Burek, C. L., Rose, N. R., and Silbergeld, E. K. (2004) Mercury exposure, malaria, and serum antinuclear/ antinucleolar antibodies in Amazon populations in Brazil: A crosssectional study. EnViron. Health 3, 11.
55. Cooper, G. S., Parks, C. G., Treadwell, E. L., St Clair, E. W., Gilkeson, G. S., and Dooley, M. A. (2004) Occupational risk factors for the development of systemic lupus erythematosus. J. Rheumatol. 31, 1928-1933.
56. Abreu Velez, A. M., Warfvinge, G., Herrera, W. L., Abreu Velez, C. E., Montoya, M. F., Hardy, D. M., Bollag, W. B., and Hashimoto, K. (2003) Detection of mercury and other undetermined materials in skin biopsies of endemic pemphigus foliaceus. Am. J. Dermatopathol. 25, 384-391.
57. Van Vleet, T. R., and Schnellmann, R. G. (2003) Toxic nephropathy: environmental chemicals. Semin. Nephrol. 23, 500-508.
58. Bates, M. N., Fawcett, J., Garrett, N., Cutress, T., and Kjellstrom, T. (2004) Health effects of dental amalgam exposure: A retrospective cohort study. Int. J. Epidemiol. 33, 894-902.
59. Nylander, M., Friberg, L., and Lind, B. (1987) Mercury concentrations in the human brain and kidneys in relation to exposure from dental amalgam fillings. Swed. Dent. J. 11, 179-187.
60. Schiraldi, M., and Monestier, M. (2009) How can a chemical element elicit complex immunopathology? Lessons from mercury-induced autoimmunity. Trends Immunol. 30, 502-509.
61. Vas, J., and Monestier, M. (2008) Immunology of mercury. Ann. N. Y. Acad. Sci. 1143, 240-267.
62. Pollard, K. M., Lee, D. K., Casiano, C. A., Bluthner, M., Johnston, M. M., and Tan, E. M. (1997) The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties. J. Immunol. 158, 3521-3528.
63. Hultman, P., and Nielsen, J. B. (1998) The effect of toxicokinetics on murine mercury-induced autoimmunity. EnViron. Res. 77, 141-148.
64. Warfvinge, K., Hansson, H., and Hultman, P. (1995) Systemic autoimmunity due to mercury vapor exposure in genetically susceptible mice: dose-response studies. Toxicol. Appl. Pharmacol. 132, 299-309.
65. Hultman, P., Lindh, U., and Horsted-Bindslev, P. (1998) Activation of the immune system and systemic immune-complex deposits in Brown Norway rats with dental amalgam restorations. J. Dent. Res. 77, 1415-1425.
66. Pollard, K. M., and Hultman, P. (1997) Effects of mercury on the immune system. Met. Ions Biol. Syst. 34, 421-440.
67. Hultman, P., Bell, L. J., Enestrom, S., and Pollard, K. M. (1993) Murine susceptibility to mercury. II. autoantibody profiles and renal immune deposits in hybrid, backcross, and H-2d congenic mice. Clin. Immunol. Immunopathol. 68, 9-20.
68. Hultman, P., Turley, S. J., Enestrom, S., Lindh, U., and Pollard, K. M. (1996) Murine genotype influences the specificity, magnitude and persistence of murine mercury-induced autoimmunity. J. Autoimmun. 9, 139-149.
69. Hultman, P., Enestrom, S., Pollard, K. M., and Tan, E. M. (1989) Anti-fibrillarin autoantibodies in mercury-treated mice. Clin. Exp. Immunol. 78, 470-477.
70. Yang, J. M., Baserga, S. J., Turley, S. J., and Pollard, K. M. (2001) Fibrillarin and other snoRNP proteins are targets of autoantibodies in xenobiotic-induced autoimmunity. Clin. Immunol. 101, 38-50.
71. Arnett, F. C., Reveille, J. D., Goldstein, R., Pollard, K. M., Leaird, K., Smith, E. A., Leroy, E. C., and Fritzler, M. J. (1996) Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum. 39, 1151-1160.
72. Takeuchi, K., Turley, S. J., Tan, E. M., and Pollard, K. M. (1995) Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity. J. Immunol. 154, 961-971.
73. Pollard, K. M., Pearson, D. L., Bluthner, M., and Tan, E. M. (2000) Proteolytic cleavage of a self-antigen following xenobiotic-induced cell death produces a fragment with novel immunogenic properties. J. Immunol. 165, 2263-2270.
74. Johansson, U., Sander, B., and Hultman, P. (1997) Effects of the murine genotype on T cell activation and cytokine production in murine mercury-induced autoimmunity. J. Autoimmun. 10, 347-355.
75. Pollard, K. M., Pearson, D. L., Hultman, P., Deane, T. N., Lindh, U., and Kono, D. H. (2001) Xenobiotic acceleration of idiopathic systemic autoimmunity in lupus-prone bxsb mice. EnViron. Health Perspect. 109, 27-33.
76. Pollard, K. M., Arnush, M., Hultman, P., and Kono, D. H. (2004) Costimulation requirements of induced murine systemic autoimmune disease. J. Immunol. 173, 5880-5887.
77. Hultman, P., Johansson, U., and Dagnaes-Hansen, F. (1995) Murine mercury-induced autoimmunity: The role of T-helper cells. J. Autoimmun. 8, 809-823.
78. van Vliet, E., Uhrberg, M., Stein, C., and Gleichmann, E. (1993) MHC control of IL-4-dependent enhancement of B cell Ia expression and Ig class switching in mice treated with mercuric chloride. Int. Arch. Allergy Immunol. 101, 392-401.
79. Reardon, C. L., and Lucas, D. O. (1987) Heavy-metal mitogenesis: Thymocyte activation by Zn++ requires 2-mercaptoethanol and lipopolysaccharide as cofactors. Immunobiology 174, 233-243.
80. Reardon, C. L., and Lucas, D. O. (1987) Heavy-metal mitogenesis: Zn++ and Hg++ induce cellular cytotoxicity and interferon production in murine T lymphocytes. Immunobiology 175, 455-469.
81. Pollard, K. M., and Landberg, G. P. (2001) The in vitro proliferation of murine lymphocytes to mercuric chloride is restricted to mature T cells and is interleukin 1 dependent. Int. Immunopharmacol. 1, 581-593.
82. Jiang, Y., and Moller, G. (1995) In vitro effects of HgCl2 on murine lymphocytes. I. Preferable activation of CD4+ T cells in a responder strain. J. Immunol. 154, 3138-3146.
83. Hu, H., Moller, G., and Abedi-Valugerdi, M. (1997) Major histocompatibility complex class II antigens are required for both cytokine production and proliferation induced by mercuric chloride in vitro. J. Autoimmun. 10, 441-446.
84. Layland, L. E., Wulferink, M., Dierkes, S., and Gleichmann, E. (2004) Drug-induced autoantibody formation in mice: Triggering by primed CD4+CD25-T cells, prevention by primed CD4+CD25+ T cells. Eur. J. Immunol. 34, 36-46.
85. Whitekus, M. J., Santini, R. P., Rosenspire, A. J., and McCabe, M. J., Jr. (1999) Protection against CD95-mediated apoptosis by inorganic mercury in Jurkat T cells. J. Immunol. 162, 7162-7170.
86. McCabe, M. J., Jr., Whitekus, M. J., Hyun, J., Eckles, K. G., McCollum, G., and Rosenspire, A. J. (2003) Inorganic mercury attenuates CD95-mediated apoptosis by interfering with formation of the death inducing signaling complex. Toxicol. Appl. Pharmacol. 190, 146-156.
87. McCabe, M. J., Jr., Eckles, K. G., Langdon, M., Clarkson, T. W., Whitekus, M. J., and Rosenspire, A. J. (2005) Attenuation of CD95-induced apoptosis by inorganic mercury: caspase-3 is not a direct target of low levels of Hg2+. Toxicol. Lett. 155, 161-170.
88. Ziemba, S. E., McCabe, M. J., Jr., and Rosenspire, A. J. (2005) Inorganic mercury dissociates preassembled Fas/CD95 receptor oligomers in T lymphocytes. Toxicol. Appl. Pharmacol. 206, 334-342.
89. Ziemba, S. E., Menard, S. L., McCabe, M. J., Jr., and Rosenspire, A. J. (2009) T-cell receptor signaling is mediated by transient Lck activity, which is inhibited by inorganic mercury. FASEB J. 23, 1663-1671.
90. Mattingly, R. R., Felczak, A., Chen, C. C., McCabe, M. J., Jr., and Rosenspire, A. J. (2001) Low concentrations of inorganic mercury inhibit Ras activation during T cell receptor-mediated signal transduction. Toxicol. Appl. Pharmacol. 176, 162-168.
91. Ziemba, S. E., Mattingly, R. R., McCabe, M. J., Jr., and Rosenspire, A. J. (2006) Inorganic mercury inhibits the activation of LAT in T-cell receptor-mediated signal transduction. Toxicol. Sci. 89, 145-153.
92. Kono, D. H., Park, M. S., Szydlik, A., Haraldsson, K. M., Kuan, J. D., Pearson, D. L., Hultman, P., and Pollard, K. M. (2001) Resistance to xenobiotic-induced autoimmunity maps to chromosome 1. J. Immunol. 167, 2396-2403.
93. Vyse, T. J., and Kotzin, B. L. (1998) Genetic susceptibility to systemic lupus erythematosus. Annu. ReV. Immunol. 16, 261-292.
94. Tsao, B. P., and Wallace, D. J. (1997) Genetics of systemic lupus erythematosus. Curr. Opin. Rheumatol. 9, 377-379.
95. Moser, K. L., Gray-McGuire, C., Kelly, J., Asundi, N., Yu, H., Bruner, G. R., Mange, M., Hogue, R., Neas, B. R., and Harley, J. B. (1999) Confirmation of genetic linkage between human systemic lupus erythematosus and chromosome 1q41. Arthritis Rheum. 42, 1902-1907.
96. Johanneson, B., Lima, G., von Salome, J., Alarcon-Segovia, D., and Alarcon-Riquelme, M. E. (2002) A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31. Am. J. Hum. Genet. 71, 1060-1071.
97. Pollard, K. M., Hultman, P., and Kono, D. H. (2005) Immunology and genetics of induced systemic autoimmunity. Autoimmun. ReV. 4, 282-288.
98. Pollard, K. M., Hultman, P., Arnush, M., Hildebrandt, B., and Kono, D. H. (2004) Immunology and genetics of xenobiotic-induced autoimmunity. In From Animal Models to Human Genetics: Research in the Induction and Pathogenicity of Autoantibodies (Conrad, K., Bachmann, M. P., Chan, E. K., Fritzler, M. J., Humbel, R. L., Sack, U., and Shoenfeld, Y., Eds.) Vol.4, pp 130-144, Pabst, Lengerich, Germany.
99. Kono, D. H., Balomenos, D., Pearson, D. L., Park, M. S., Hildebrandt, B., Hultman, P., and Pollard, K. M. (1998) The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-gamma and not Th1/Th2 imbalance. J. Immunol. 161, 234-240.
100. Cauvi, D. M., Cauvi, G., and Pollard, K. M. (2007) Reduced expression of decay-accelerating factor 1 on CD4+ T cells in murine systemic autoimmune disease. Arthritis Rheum. 56, 1934-1944.
101. Heeger, P. S., Lalli, P. N., Lin, F., Valujskikh, A., Liu, J., Muqim, N., Xu, Y., and Medof, M. E. (2005) Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201, 1523-1530.
102. Liu, J., Miwa, T., Hilliard, B., Chen, Y., Lambris, J. D., Wells, A. D., and Song, W. C. (2005) The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201, 567-577.
103. Miwa, T., Maldonado, M. A., Zhou, L., Yamada, K., Gilkeson, G. S., Eisenberg, R. A., and Song, W. C. (2007) Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and-independent mechanisms. Am. J. Pathol. 170, 1258-1266.
104. Haggqvist, B., and Hultman, P. (2001) Murine metal-induced systemic autoimmunity: Baseline and stimulated cytokine mRNA expression in genetically susceptible and resistant strains. Clin. Exp. Immunol. 126, 157-164.
105. Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A., and Fu, X. Y. (1997) Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell. Biol. 17, 5328-5337.
106. Suk, K., Chang, I., Kim, Y. H., Kim, S., Kim, J. Y., Kim, H., and Lee, M. S. (2001) Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. J. Biol. Chem. 276, 13153-13159.
107. Pollard, K. M., Pearson, D. L., Hultman, P., Hildebrandt, B., and Kono, D. H. (1999) Lupus-prone mice as models to study xenobioticinduced acceleration of systemic autoimmunity. EnViron. Health Perspect. 107 (Suppl. 5), 729-735.
108. Burek, C. L., and Rose, N. R. (2008) Autoimmune thyroiditis and ROS. Autoimmun. ReV. 7, 530-537.
109. Bournaud, C., and Orgiazzi, J. J. (2003) Iodine excess and thyroid autoimmunity. J. Endocrinol. InVest. 26, 49-56.
110. Tomer, Y., and Huber, A. (2009) The etiology of autoimmune thyroid disease: a story of genes and environment. J. Autoimmun. 32, 231-239.
111. Vladutiu, A. O. (1989) Experimental autoimmune thyroiditis in mice chronically treated from birth with anti-IgM antibodies. Cell. Immunol. 121, 49-59.
112. Stafford, E. A., and Rose, N. R. (2000) Newer insights into the pathogenesis of experimental autoimmune thyroiditis. Int. ReV. Immunol. 19, 501-533.
113. Vladutiu, A. O., and Rose, N. R. (1971) Autoimmune murine thyroiditis relation to histocompatibility (H-2) type. Science 174, 1137-1139.
114. Tang, H., Sharp, G. C., Peterson, K. P., and Braley-Mullen, H. (1998) IFN-gamma-deficient mice develop severe granulomatous experimental autoimmune thyroiditis with eosinophil infiltration in thyroids. J. Immunol. 160, 5105-5112.
115. Alimi, E., Huang, S., Brazillet, M. P., and Charreire, J. (1998) Experimental autoimmune thyroiditis (EAT) in mice lacking the IFNgamma receptor gene. Eur. J. Immunol. 28, 201-208.
116. Jin, Z., Mori, K., Fujimori, K., Hoshikawa, S., Tani, J., Satoh, J., Ito, S., Satomi, S., and Yoshida, K. (2004) Experimental autoimmune thyroiditis in nonobese diabetic mice lacking interferon regulatory factor-1. Clin. Immunol. 113, 187-192.
117. Vladutiu, A. O., and Sulkowski, E. (1980) Inhibition of murine autoimmune thyroiditis by interferon. Biomedicine 33, 173-174.
118. Rasooly, L., Burek, C. L., and Rose, N. R. (1996) Iodine-induced autoimmune thyroiditis in NOD-H-2h4 mice. Clin. Immunol. Immunopathol. 81, 287-292.
119. Hutchings, P. R., Verma, S., Phillips, J. M., Harach, S. Z., Howlett, S., and Cooke, A. (1999) Both CD4(+) T cells and CD8(+) T cells are required for iodine accelerated thyroiditis in NOD mice. Cell. Immunol. 192, 113-121.
120. Braley-Mullen, H., and Yu, S. (2000) Early requirement for B cells for development of spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J. Immunol. 165, 7262-7269.
121. Yu, S., Sharp, G. C., and Braley-Mullen, H. (2002) Dual roles for IFN-gamma, but not for IL-4, in spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J. Immunol. 169, 3999-4007.
122. Nagayama, Y., Horie, I., Saitoh, O., Nakahara, M., and Abiru, N. (2007) CD4+CD25+ naturally occurring regulatory T cells and not lymphopenia play a role in the pathogenesis of iodide-induced autoimmune thyroiditis in NOD-H2h4 mice. J. Autoimmun. 29, 195-202.
123. Fang, Y., Yu, S., and Braley-Mullen, H. (2007) Contrasting roles of IFN-gamma in murine models of autoimmune thyroid diseases. Thyroid 17, 989-994.
124. Obermayer-Straub, P., Strassburg, C. P., and Manns, M. P. (2000) Autoimmune hepatitis. J. Hepatol. 32, 181-197.
125. Rieger, R., and Gershwin, M. E. (2007) The X and why of xenobiotics in primary biliary cirrhosis. J. Autoimmun. 28, 76-84.
126. Leung, P. S., Park, O., Tsuneyama, K., Kurth, M. J., Lam, K. S., Ansari, A. A., Coppel, R. L., and Gershwin, M. E. (2007) Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J. Immunol. 179, 2651-2657.
127. Wakabayashi, K., Yoshida, K., Leung, P. S., Moritoki, Y., Yang, G. X., Tsuneyama, K., Lian, Z. X., Hibi, T., Ansari, A. A., Wicker, L. S., Ridgway, W. M., Coppel, R. L., Mackay, I. R., and Gershwin, M. E. (2009) Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin. Exp. Immunol. 155, 577-586.
128. Wakabayashi, K., Lian, Z. X., Leung, P. S., Moritoki, Y., Tsuneyama, K., Kurth, M. J., Lam, K. S., Yoshida, K., Yang, G. X., Hibi, T., Ansari, A. A., Ridgway, W. M., Coppel, R. L., Mackay, I. R., and Gershwin, M. E. (2008) Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 48, 531-540.
129. Selmi, C., and Gershwin, M. E. (2009) The role of environmental factors in primary biliary cirrhosis. Trends Immunol. 30, 415-420.
130. Oertelt, S., Ridgway, W. M., Ansari, A. A., Coppel, R. L., and Gershwin, M. E. (2007) Murine models of primary biliary cirrhosis: Comparisons and contrasts. Hepatol. Res. 37 (Suppl. 3), S365-S369.
131. Reeves, W. H., Lee, P. Y., Weinstein, J. S., Satoh, M., and Lu, L. (2009) Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 30, 455-464.
132. Cruickshank, B., and Thomas, M. J. (1984) Mineral oil (follicular) lipidosis: II. Histologic studies of spleen, liver, lymph nodes, and bone marrow. Hum. Pathol. 15, 731-737.
133. Satoh, M., Kuroda, Y., Yoshida, H., Behney, K. M., Mizutani, A., Akaogi, J., Nacionales, D. C., Lorenson, T. D., Rosenbauer, R. J., and Reeves, W. H. (2003) Induction of lupus autoantibodies by adjuvants. J. Autoimmun. 21, 1-9.
134. Yoshida, H., Satoh, M., Behney, K. M., Lee, C. G., Richards, H. B., Shaheen, V. M., Yang, J. Q., Singh, R. R., and Reeves, W. H. (2002) Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice. Arthritis Rheum. 46, 2235-2244.
135. Richards, H. B., Satoh, M., Shaw, M., Libert, C., Poli, V., and Reeves, W. H. (1998) Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J. Exp. Med. 188, 985-990.
136. Nacionales, D. C., Kelly-Scumpia, K. M., Lee, P. Y., Weinstein, J. S., Lyons, R., Sobel, E., Satoh, M., and Reeves, W. H. (2007) Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56, 3770-3783.
137. Baechler, E. C., Gregersen, P. K., and Behrens, T. W. (2004) The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16, 801-807.
138. Satoh, M., Weintraub, J. P., Yoshida, H., Shaheen, V. M., Richards, H. B., Shaw, M., and Reeves, W. H. (2000) Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus. J. Immunol. 165, 1036-1043.
139. Andrews, B. S., Eisenberg, R. A., Theofilopoulos, A. N., Izui, S., Wilson, C. B., McConahey, P. J., Murphy, E. D., Roths, J. B., and Dixon, F. J. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148, 1198-1215.
140. Hron, J. D., and Peng, S. L. (2004) Type I IFN protects against murine lupus. J. Immunol. 173, 2134-2142.
141. Young, A. L., Giesy, J. P., Jones, P. D., and Newton, M. (2004) Environmental fate and bioavailability of Agent Orange and its associated dioxin during the Vietnam War. EnViron. Sci. Pollut. Res. Int. 11, 359-370.
142. Jennings, A. M., Wild, G., Ward, J. D., and Ward, A. M. (1988) Immunological abnormalities 17 years after accidental exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Br. J. Ind. Med. 45, 701-704.
143. Kim, H. A., Kim, E. M., Park, Y. C., Yu, J. Y., Hong, S. K., Jeon, S. H., Park, K. L., Hur, S. J., and Heo, Y. (2003) Immunotoxicological effects of Agent Orange exposure to the Vietnam War Korean veterans. Ind. Health 41, 158-166.
144. Tonn, T., Esser, C., Schneider, E. M., Steinmann-Steiner-Haldenstatt, W., and Gleichmann, E. (1996) Persistence of decreased T-helper cell function in industrial workers 20 years after exposure to 2,3,7,8-tetrachlorodibenzo-p- dioxin. EnViron. Health Perspect. 104, 422-426.
145. Baccarelli, A., Mocarelli, P., Patterson, D. G., Jr., Bonzini, M., Pesatori, A. C., Caporaso, N., and Landi, M. T. (2002) Immunologic effects of dioxin: New results from Seveso and comparison with other studies. EnViron. Health Perspect. 110, 1169-1173.
146. Signorini, S., Gerthoux, P. M., Dassi, C., Cazzaniga, M., Brambilla, P., Vincoli, N., and Mocarelli, P. (2000) Environmental exposure to dioxin: the Seveso experience. Andrologia 32, 263-270.
147. Wolfe, W. H., Michalek, J. E., Miner, J. C., Rahe, A., Silva, J., Thomas, W. F., Grubbs, W. D., Lustik, M. B., Karrison, T. G., Roegner, R. H., et al. (1990) Health status of Air Force veterans occupationally exposed to herbicides in Vietnam. I. Physical health. J. Am. Med. Assoc. 264, 1824-1831.
148. Funatake, C. J., Marshall, N. B., Steppan, L. B., Mourich, D. V., and Kerkvliet, N. I. (2005) Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+ CD25+ cells with characteristics of regulatory T cells. J. Immunol. 175, 4184-4188.
149. Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., and Weiner, H. L. (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453, 65-71.
150. Esser, C., Rannug, A., and Stockinger, B. (2009) The aryl hydrocarbon receptor in immunity. Trends Immunol. 30, 447-454.
151. Ishimaru, N., Takagi, A., Kohashi, M., Yamada, A., Arakaki, R., Kanno, J., and Hayashi, Y. (2009) Neonatal exposure to low-dose 2,3,7,8- tetrachlorodibenzo-p-dioxin causes autoimmunity due to the disruption of T cell tolerance. J. Immunol. 182, 6576-6586.
152. Mathis, D., and Benoist, C. (2009) Aire. Annu. ReV. Immunol. 27, 287-312.
153. Cai, P., Konig, R., Boor, P. J., Kondraganti, S., Kaphalia, B. S., Khan, M. F., and Ansari, G. A. (2008) Chronic exposure to trichloroethene causes early onset of SLE-like disease in female MRL +/+ mice. Toxicol. Appl. Pharmacol. 228, 68-75.
154. Blossom, S. J., Doss, J. C., and Gilbert, K. M. (2007) Chronic exposure to a trichloroethylene metabolite in autoimmune-prone MRL+/+ mice promotes immune modulation and alopecia. Toxicol. Sci. 95, 401-411.
155. Gilbert, K. M., Pumford, N. R., and Blossom, S. J. (2006) Environmental contaminant trichloroethylene promotes autoimmune disease and inhibits T-cell apoptosis in MRL(+/+) mice. J. Immunotoxicol. 3, 263-267.
156. Blossom, S. J., and Doss, J. C. (2007) Trichloroethylene alters central and peripheral immune function in autoimmune-prone MRL(+/+) mice following continuous developmental and early life exposure. J. Immunotoxicol. 4, 129-141.
157. Cooper, G. S., Makris, S. L., Nietert, P. J., and Jinot, J. (2009) Evidence of autoimmune-related effects of trichloroethylene exposure from studies in mice and humans. EnViron. Health Perspect. 117, 696-702.
158. Parks, C. G., and Cooper, G. S. (2005) Occupational exposures and risk of systemic lupus erythematosus. Autoimmunity 38, 497-506.
159. Michielsen, C. C., van Loveren, H., and Vos, J. G. (1999) The role of the immune system in hexachlorobenzene-induced toxicity. EnViron. Health Perspect. 107 (Suppl. 5), 783-792.
160. Cripps, D. J., Peters, H. A., Gocmen, A., and Dogramici, I. (1984) Porphyria turcica due to hexachlorobenzene: A 20 to 30 year followup study on 204 patients. Br. J. Dermatol. 111, 413-422.
161. Daniel, V., Huber, W., Bauer, K., Suesal, C., Conradt, C., and Opelz, G. (2001) Associations of blood levels of PCB, HCHS, and HCB with numbers of lymphocyte subpopulations, in vitro lymphocyte response, plasma cytokine levels, and immunoglobulin autoantibodies. EnViron. Health Perspect. 109, 173-178.
162. Ezendam, J., Vos, J. G., and Pieters, R. (2005) Research articles mechanisms of hexachlorobenzene-induced adverse immune effects in brown norway rats. J. Immunotoxicol. 1, 167-175.
163. Yurino, H., Ishikawa, S., Sato, T., Akadegawa, K., Ito, T., Ueha, S., Inadera, H., and Matsushima, K. (2004) Endocrine disruptors (environmental estrogens) enhance autoantibody production by B1 cells. Toxicol. Sci. 81, 139-147.
164. Sobel, E. S., Gianini, J., Butfiloski, E. J., Croker, B. P., Schiffenbauer, J., and Roberts, S. M. (2005) Acceleration of autoimmunity by organochlorine pesticides in (NZB x NZW)F1 mice. EnViron. Health Perspect. 113, 323-328.
165. Leffel, E. K., Wolf, C., Poklis, A., and White, K. L., Jr. (2003) Drinking water exposure to cadmium, an environmental contaminant, results in the exacerbation of autoimmune disease in the murine model. Toxicology 188, 233-250.
166. Hudson, C. A., Cao, L., Kasten-Jolly, J., Kirkwood, J. N., and Lawrence, D. A. (2003) Susceptibility of lupus-prone NZM mouse strains to lead exacerbation of systemic lupus erythematosus symptoms. J. Toxicol. EnViron. Health A 66, 895-918.
167. Pumford, N. R., and Halmes, N. C. (1997) Protein targets of xenobiotic reactive intermediates. Annu. ReV. Pharmacol. Toxicol. 37, 91-117.
168. Kono, D. H., Haraldsson, M. K., Lawson, B. R., Pollard, K. M., Koh, Y. T., Du, X., Arnold, C. N., Baccala, R., Silverman, G. J., Beutler, B. A., and Theofilopoulos, A. N. (2009) Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc. Natl. Acad. Sci. U.S.A. 106, 12061-12066.